ABSTRACT
Introduction
Genotypic antiretroviral resistance testing (GART) has been recommended for primary resistance prior to starting antiretroviral therapy (ART) and for the management of treatment failure in HIV-infected patients [1] . While the prevalence of primary ART resistance has been widely published and reviewed, fewer reports have described such prevalence among ART-treated patients, where patterns and expansion of resistance may have arisen from the selection of variants from patients failing their ART [2] . As part of the HIV Cost and Service Utilization Study in the US during 1996-1998, 65% of 208,900 HIV-infected adults receiving ART had HIV RNA > 500 copies/mL, and approximately 76% of these patients had resistance against more than one drug [3] . Resistance in this study was significantly higher among patients with history of ART, advanced HIV disease, high viremia, and lowest CD4 counts [3] . The prevalence of resistance against one or more drugs has been reported to be between 55% to 88% among viremic samples in France [4] and US [5] and between 35% to 88% among ART-treated patients in France [2] , the UK [6] , Thailand [7] , and Spain [8] .
In the present study, we assessed the prevalence of ART genotypic mutations and resistance among our viremic HIV-infected patients, ART drug utilization, and risks for HIV acquisition during the period 2001-2006 in the District of Columbia, the metropolitan area with the highest HIV prevalence within the United States [9] .
Materials and Methods
The Veterans Affairs Medical Center located in Washington, DC (VAMC-DC) is a tertiary care facility serving Veterans in the greater metropolitan area of the District of Columbia. This study was reviewed in accordance with the ethical standards on human experimentation and with the Helsinki Declaration of 1975 and its revision in 2000 and approved by the Human Studies Subcommittee and Research and Development Committee of the VAMC-DC. This retrospective, cross-sectional study examined deidentified, linked HIV RNA and GART results during September 2001 through November 2006 at the VAMC-DC. HIV RNA was quantified using Versant HIV RNA 3.0 Assay (bDNA) (Siemens Medical Solutions Diagnostics, Tarrytown, NY). GART was assayed using TruGene HIV-1 Genotyping Kit (Siemens Medical Solutions Diagnostics, Tarrytown, NY) using versions 3.0 through 11.0 interpretation rules; mutations in the envelope gene for resistance to entry inhibitors and in the integrase gene for resistance to integrase inhibitors were not assessed by this assay. All tests had been performed for purposes of patient care. GART was performed on clinical samples with detectable viremia including those in the range of 75 -1000 copies/mL, as we had previously shown reliable results in our laboratory [10, 11] .
Aggregated data on the numbers of new HIV diagnoses, patients in HIV care and on ART, and risk factors for HIV acquisition were obtained from our local Clinical Case Registry for HIV. Drug class resistance mutations were based on the IAS-USA December 2010 update [12] .
HIV RNA and GART data were analyzed using frequency distribution of mutations and interpreted resistance for nucleoside/nucleotide reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI) classes. In addition, χ 2 analyses were performed for genotypic mutations and interpreted drug resistance with significance taken at <0.05 using STATA (version 8.0, StataCorp LP, College Station, TX).
Results
Our study evaluated 990 viremic samples with GART results, as summarized in Table 1 , with data from our clinic population. Since new HIV diagnoses accounted for 4% -9% of tested patients, most GART were presumably performed for ART failure; however, this could not be confirmed, as we used de-identified data. The proportion of any detected mutations diminished from 100% in 2001 to 95% in 2006. The median rates of mutations to NRTI, NNRTI and PI drug classes were 69%, 47% and 93% during this time, respectively. Over the 6-year period, this decrease was attributed to RT mutations, which fell significantly by 13%, while Pr mutations remained relatively stable.
For RT mutations, both NRTI and NNRTI drug classes showed steady decreases in mutations over the study period of 15% and 20%, respectively. The most prevalent NRTI mutations included M184V/I and thymidine analogue-associated mutations (TAMs) such as M41L, D67N, K70R, L210W, T215V/F, and T219O/E. The mutation rate for M184V/I rose from 38% to 43%, while rates for TAMs fell from 58% to 39%. Rates of multi-NRTI resistance due to 69 insertion complex and 151 complex remained relatively stable. The most prevalent NNRTI mutation was K103N, dropping from 40% to 26%, while the prevalence of V106M/A and Y188L/C/H remained at 0 -2% and 3% -8%, respectively. Table 2 summarizes the interpreted resistance for ART drugs. Among GART performed on viremic samples, detected resistance to one ART drug ranged from 2% to 56% in 2001 and 0.6% to 43% in 2006. Rates of resistance for any NRTI, NNRTI and PI drugs were 2% -48%, 54% -56% and 8% -42% in 2001, respectively, compared to 9% -43%, 33% -36% and 0.6% -26% in 2006, respectively. For specific NRTI drugs, resistance remained stable for abacavir and lamivudine/emtricitabine, significantly increased for tenofovir, but declined for didanosine, stavudine and zidovudine. Resistance to efavirenz and nevirapine decreased by at least 20%. Among PI drugs, only atazanavir demonstrated a significant rise in resistance during its years of use from 2003 to 2006, while indinavir and nelfinavir resistance diminished, and amprenavir/fosamprenavir and lopinavir-ritonavir resistance remained without significant Table 4 summarizes the 13 specific risk factors for HIV acquisition disclosed by our HIV-infected patients in care during this study period. Sexual contacts and injection drug use (IDU) accounted for 77% and 22% of our patients' acquisition risks, respectively. Continuation of such behavioral risks would allow for potential transmission of resistant HIV from these viremic patients.
Discussion
There has been one report evaluating rates of HIV genotypic mutations or antiretroviral resistance in the chronically infected Veteran population [13] ; there have been none for the District of Columbia, which has the highest rate of persons living with HIV/AIDS in the United States [9] . A prior study done at the VA Medical Center in San Francisco had noted the prevalence of mutations to NRTI, NNRTI, and PI among their patients during 1996-1997 and 1999-2000 to be 30%, 14%, and 16%, respectively [13] . In our study at the VAMC-DC during 2001-2006, the prevalence of any genotypic mutations were much higher with median rates of mutations to NRTI, NNRTI and PI classes at 69%, 47% and 93%, respectively.
Among our viremic samples during 2001-2006, the prevalence of any detected mutations fell from 100% to 95%, a decreasing trend that was seen primarily for NNRTI and NRTI classes of ART. In this period, NNRTI class mutations declined by 20% with significant drops in efavirenz and nevirapine resistance. During the same period, patients' use of efavirenz (either alone or in combination) increased but nevirapine use remained relatively stable. During 2001-2006, NRTI mutations decreased by 15% with declining resistance seen for all NRTI drugs except abacavir, lamivudine/emtricitabine and tenofovir. Our patients' use of any tenofovir and lamivudine/emtricitabine increased, and abacavir use remained stable.
During our study period, Pr mutations remained high but relatively unchanged. Resistance was noted to increase only for atazanavir from 2003 to 2006 due to our patients' accumulations of and rising mutation rates for K20R/I, E34Q, M36I, M46I/L, I50L, F53L, I54M, D60E, [12, 14, 15] . This increased resistance paralleled our patients' use of atazanavir during the same 4-year period.
Some resistance trends seem discordant with ART utilization for certain drugs such as didanosine, zidovudine, efavirenz and nevirapine, where mutation rates dropped despite stable or higher drug usage rates. Our mutation data were solely from de-identified persons with detectable viremia whose specific ART regimens were not known, while our ART utilization data were from our entire clinic population on ART including those with viral suppression. Importantly, ART-treated patients without detectable viremia ( Table 1) Another consideration for the discordance between drug resistance and utilization may be mutations in the connection domain between RT codons 316 and 437 which connect the DNA polymerase and RNase domains. Connection domain mutations were associated with reduced NRTI susceptibility in a study of ART-experienced patients with detectable viremia [16] . As we cannot assess for connection domain mutations in our assay, we do not know if connection domain mutations may have had an impact on the primary RT mutations detected in our GART samples, particularly during the early part of our study period.
A limitation of our de-identified data is the lack of ART history, as historical genotype evaluations rather than a cross-sectional study may give more insight into the prevalence of resistance [17] . Our ART utilization provided only aggregated data for our entire clinic population where a large proportion had viral suppression and thus did not require GART. In addition, our patients' adherence to ART was not evaluated.
The general decrease in transmitted drug resistance over time may be due to wider use of regimens that suppress viral loads or possible selection biases that test for people with fewer mutations [18] . Given the reliability of GART in the viremia range 75 -1000 copies/mL in our laboratory [10, 11] , mutations may be detected earlier among our patients, as their ART resistance emerged.
Decreasing patterns of resistance may likely infer increase in wild type virus with reservoir seeding of more resistant strains. Treating these patients may prove to be difficult, if the true gamut of mutations is not fully captured on testing. More sensitive techniques testing for HIV resistance mutations in peripheral blood mononuclear cells have been used to unmask reservoir viruses [19] ; these studies were not pursued in our patients.
Major concerns for viremic patients are contributions to the community viral load and the transmission of resistant virus to others. The District of Columbia has had the highest rate of HIV/AIDS in the United States, affecting 3.2% of persons over age 12 [9] . Our patients' disclosed HIV acquisition risks from sexual contacts (77%) and IDU (22%) paralleled those reported by the District of Columbia through 2009, where MSM sexual contact (38.8%), heterosexual contact (27.2%) and IDU (16.4%) were the 3 leading modes of transmission among those living with HIV/AIDS [9] . Behavioral risks among our viremic patients had the potential for transmission of resistant HIV into the community at large, despite the District of Columbia's programs in harm reduction through large scale free condom distribution and needle exchange [9] . Unsafe sexual activities decreased among surveyed patients with ART use [20] , ART adherence [20, 21] , viral suppression [20] , optimism about HIV prognosis [22] , and prevention interventions [23] . However, suboptimal adherence and current or past history of drug and/or alcohol abuse were among the predictors for virologic failure [24] . In addition, patients reporting IDU with or without opiate substitution treatment had a 2-to 3-fold higher non-adherence to ART compared with abstinent patients [25] . These persons with reduced adherence to ART may engage in more risk behaviors, thereby allowing further transmission of resistant HIV.
The high prevalence and changing patterns of HIV genotypic mutations and drug resistance among our viremic patients have pivotal impact not only on our ART management but also on potential transmission of resistant HIV into the metropolitan community with the highest HIV prevalence within the United States.
